Clinical subtypes and prognosis in breast cancer according to parity: a nationwide study in Korean Breast Cancer Society

[1]  P. Hannaford,et al.  Contemporary Hormonal Contraception and the Risk of Breast Cancer , 2017, The New England journal of medicine.

[2]  S. Cross,et al.  Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study , 2017, Breast Cancer Research.

[3]  S. Hofvind,et al.  Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program , 2017, Breast Cancer Research.

[4]  J. Balko,et al.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease , 2016, Nature Reviews Clinical Oncology.

[5]  L. Santoro,et al.  Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. , 2016, Cancer treatment reviews.

[6]  A. Jemal,et al.  Breastfeeding and breast cancer risk by receptor status--a systematic review and meta-analysis. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  A. Partridge,et al.  Biology of breast cancer in young women , 2014, Breast Cancer Research.

[8]  G. Giles,et al.  Reproductive risk factors and oestrogen/progesterone receptor-negative breast cancer in the Breast Cancer Family Registry , 2014, British Journal of Cancer.

[9]  R. Schwab,et al.  Reproductive risk factors and breast cancer subtypes: a review of the literature , 2014, Breast Cancer Research and Treatment.

[10]  S. Yao,et al.  Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women’s Circle of Health Study , 2013, Cancer Causes & Control.

[11]  V. Hasselblad,et al.  Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic Review , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[12]  J. Palmer,et al.  Postpartum remodeling, lactation, and breast cancer risk: summary of a National Cancer Institute-sponsored workshop. , 2013, Journal of the National Cancer Institute.

[13]  E. Perez,et al.  Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. , 2013 .

[14]  E. Perez,et al.  Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  L. Vatten,et al.  Association of time since last birth, age at first birth and parity with breast cancer survival among parous women: A register‐based study from Norway , 2013, International journal of cancer.

[16]  K. Choi,et al.  Trends in Cancer Screening Rates among Korean Men and Women: Results from the Korean National Cancer Screening Survey (KNCSS), 2004-2011 , 2012, Cancer research and treatment : official journal of Korean Cancer Association.

[17]  M. García-Closas,et al.  Analysis of terminal duct lobular unit involution in luminal A and basal breast cancers , 2012, Breast Cancer Research.

[18]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[19]  Kevin W Eliceiri,et al.  Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2 , 2011, Nature Medicine.

[20]  K. Choi,et al.  Trends in Cancer Screening Rates among Korean Men and Women: Results from the Korean National Cancer Screening Survey (KNCSS), 2004-2010 , 2011, Cancer research and treatment : official journal of Korean Cancer Association.

[21]  M. Hammond,et al.  Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Prentice,et al.  Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. , 2011, Journal of the National Cancer Institute.

[23]  Victoria L. Cafourek,et al.  Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. , 2011, Journal of the National Cancer Institute.

[24]  G. Hortobagyi,et al.  Higher parity and shorter breastfeeding duration , 2010, Cancer.

[25]  V. Borges,et al.  Epithelial and Mesenchymal Cell Biology Alternatively Activated Macrophages and Collagen Remodeling Characterize the Postpartum Involuting Mammary Gland across Species , 2010 .

[26]  L. Holmberg,et al.  Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment , 2009, PloS one.

[27]  G. Landberg,et al.  Parity in relation to survival following breast cancer. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[28]  M. Pike,et al.  American Journal of Epidemiology Original Contribution Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status the Multiethnic Cohort Study , 2022 .

[29]  D. Easton,et al.  Risk factors for the incidence of breast cancer: do they affect survival from the disease? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Karlsson,et al.  Long-term inequalities in breast cancer survival – a ten year follow-up study of patients managed within a National Health Care System (Sweden) , 2008, Acta oncologica.

[31]  M. Pike,et al.  Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies , 2006, Breast Cancer Research.

[32]  P. Hall,et al.  Childbirth and breast cancer prognosis , 2004, International journal of cancer.

[33]  G. Dontu,et al.  Breast cancer, stem/progenitor cells and the estrogen receptor , 2004, Trends in Endocrinology & Metabolism.

[34]  F. Talamantes,et al.  Prevention of mammary carcinogenesis by short-term estrogen and progestin treatments , 2003, Breast Cancer Research.

[35]  J. Ranstam,et al.  Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease , 2002, The Lancet.

[36]  R. Goldbohm,et al.  Breast cancer and breastfeeding: Collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease , 2002 .

[37]  K. Hill.  The demography of menopause. , 1996, Maturitas.

[38]  H. Adami,et al.  Transient increase in the risk of breast cancer after giving birth. , 1994, The New England journal of medicine.

[39]  B. Asselain,et al.  Age as prognostic factor in premenopausal breast carcinoma , 1993, The Lancet.

[40]  C. Lowe,et al.  Age at first birth and breast cancer risk. , 1970, Bulletin of the World Health Organization.